Elena Ladich (Hollywood, USA) and Roger Greenhalgh (London, UK) discuss the current uncertainty surrounding the use of paclitaxel devices and the need for individual patient-level data analyses going forward to better understand the mortality signal raised by the Katsanos et al meta-analysis.

Ladich believes that “we need to take a step back” and evaluate the data because “the truth takes time”.

Meanwhile, Greenhalgh, emphasises the trade-off in terms of risk and benefit that clinicians have to consider when using these devices in appropriately consented patients.